Alyeska Investment Group
BLPH

Alyeska Investment Group’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Alyeska Investment Group’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,286
Closed -$80K – 587
2016
Q4 		$80K Buy
10,286
+82
+0.8% +$1.14K ﹤0.01% 461
2016
Q3 		$214K Buy
10,204
+406
+4% +$9.8K ﹤0.01% 440
2016
Q2 		$260K Buy
9,798
+199
+2% +$5.46K ﹤0.01% 414
2016
Q1 		$354K Buy
9,599
+297
+3% +$11K ﹤0.01% 370
2015
Q4 		$413K Buy
9,302
+537
+6% +$26K ﹤0.01% 358
2015
Q3 		$682K Buy
8,765
+2,386
+37% +$184K 0.01% 409
2015
Q2 		$759K Buy
6,379
+104
+2% +$14.1K 0.01% 424
2015
Q1 		$864K Buy
+6,275
New +$977K 0.01% 442

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Alyeska Investment Group's BLPH Position: Q1 2017 in Review

Alyeska Investment Group sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q1 2017, closing a stake of 10,286 shares — an estimated $80K sold.

Alyeska Investment Group first reported a position in BLPH in Q1 2015 and held it in 8 quarters. The position peaked at $864K in Q1 2015. 13 funds tracked by Wall St. Rank hold BLPH as of Q1 2017.

  • Alyeska Investment Group reported no remaining Bellerophon Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Alyeska Investment Group sold 10,286 Bellerophon Therapeutics, Inc. shares in Q1 2017, an estimated $80K.
  • Alyeska Investment Group first reported a position in Bellerophon Therapeutics, Inc. in Q1 2015 and held it in 8 quarters.
  • Alyeska Investment Group's Bellerophon Therapeutics, Inc. position peaked at $864K in Q1 2015.
  • 13 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q1 2017.

Based on Alyeska Investment Group's 13F filing for Q1 2017, filed 15 May 2017.